Affymax and Takeda aim to submit Hematide to the FDA in 2011

08/5/2010 | Bloomberg Businessweek

Affymax and Japanese partner Takeda Pharmaceutical plan to file for FDA approval of anemia treatment Hematide during the first half of next year. Affymax said it will pursue an application for the treatment of anemia in dialysis patients and continue evaluating the drug's nondialysis use.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA